Study on the Efficacy and Safety of Transarterial Chemoembolization Combined with Targeted Immunotherapy in Patients with Unresectable Hepatocellular Carcinoma
1 other identifier
observational
70
0 countries
N/A
Brief Summary
This study is a single-center, single-arm, prospective study. It enrolls patients with unresectable hepatocellular carcinoma (HCC). The study aims to investigate the efficacy and safety of transarterial chemoembolization combined with targeted immunotherapy in patients with unresectable HCC, providing treatment guidance for these patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jul 2025
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 19, 2024
CompletedFirst Posted
Study publicly available on registry
December 4, 2024
CompletedStudy Start
First participant enrolled
July 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
December 4, 2024
November 1, 2024
1.4 years
November 19, 2024
November 28, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Efficacy Evaluation
The time from the date of the first dose of lenvatinib to disease progression or death from any cause.
tree years
Eligibility Criteria
Unresectable Liver Cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Yao Xielead
Related Publications (1)
Li M, Hao J, Jiang T, Deng W, Lu H, Wang S, Wan G, Xie Y, Yi W. Maternal and neonatal safety of COVID-19 vaccination during the peri-pregnancy period: A prospective study. J Med Virol. 2023 Jan;95(1):e28378. doi: 10.1002/jmv.28378.
PMID: 36478410BACKGROUND
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- professor
Study Record Dates
First Submitted
November 19, 2024
First Posted
December 4, 2024
Study Start
July 1, 2025
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2026
Last Updated
December 4, 2024
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will not share